Index

Page locators in bold indicate tables. Page locators in italics indicate figures.

a
absent ejaculation (male) 131–132
absent orgasm 224
ACOG see American Congress of Obstetricians and Gynecologists
acupuncture 290
acute venous dilation 266
adjunctive modalities 306–308
adrenergic regulation 110, 116
AEE see ambivalence over emotional expression
afferent pathway
arousal disorders 111–112
female orgasm disorder 225
orgasm disorders 186
pelvic and sexual pain disorders 301
sexual pain disorders 259, 264, 267
agomelatine 84
alprostadil 152–153
Althof, Stan 3
AMAG Pharmaceuticals 341–342
ambivalence over emotional expression (AEE) 285
American Congress of Obstetricians and Gynecologists (ACOG) 249
amphetamine 241
amygdala 186, 189, 227
androgens see individual hormones; ovarian steroid hormones
delta5-androstenediol 148
delta4-androstenedione 61–63, 71, 86
anorgasmia 224
ANSA see autonomic nervous system
antibiotics 324
anticonvulsants 333
antidepressants
dyspareunia and vulvovaginal pain 324, 332
female orgasmic illness syndrome 241
future developments and research 342–343
hypoactive sexual desire disorder 79, 83–84
neurobiological endocrinology 70–71
antihistamines 241
antipsychotics 79
anxiety
arousal disorders 129
dyspareunia and vulvovaginal pain 324
pelvic and sexual pain disorders 306
persistent genital arousal disorder 163
provoked vestibulodynia 283, 286–288
aquaporin (AQP) 112
arousal disorders
anatomy and physiology of arousal 107–125
assessment of sexual response 134–135, 135, 136
diagnosis of FGAD 149–150
diagnosis of PGAD 165–166
DSM classification 103–104
effects of partner dysfunction in women 131–132
epidemiology 105
ESSM assessment methods 14
etiology of sexual arousal 128–131, 161–162
genital and extragenital responses 107, 108

© 2018 John Wiley & Sons Ltd. Published 2018 by John Wiley & Sons Ltd.
arousal disorders (cont’d)
  health and lifespan 132–134
  considerations 132–134
  hemodynamics 108–110, 109, 115–116
  ISSWSH classification 104–105
  models of arousal 127–128
  modulation by sex steroid hormones 113–117, 114
  neurobiological endocrinology 148–150, 153–155
  neurologic interventions 156
  neurotransmitters 110–112, 116
  nonpharmacological treatments 135–136
  nosology 103–105, 147, 162–163
  pathophysiology and medical management of FGAD 145–160
  pathophysiology and medical management of PGAD 161–171
  physiology of female genital arousal responses 146
  PRESIDE study 105
  prevalence of PGAD in the United States 161
  psychological management 127–144, 150, 162, 166
  risk factors for women with FGAD 147–148
  risk factors for women with PGAD 163–165
  subjective arousal 107–108, 146–147
  treatment of FGAD 150–156
  treatment of PGAD 166–168
  vaginal lubrication 112–113, 115–116
  autoimmune disorders 300
  autonomic nervous system (ANS) 110–112

b
  balanitis 212
  Bartholin gland 325–326, 325, 326
  Basson, Rosemary 30, 31, 43, 128, 200, 200
  biofeedback 307, 332
  biomechanical abnormalities 297, 300
  biopsychosocial model 53–55, 54
  bladder pain syndrome 259, 326–327, 328
  bladder retraining 306
  body image 129
  botulinum toxin 308, 331–332
  bowel retraining 306
  breathing practice 306
  bremelanotide 45–46, 153, 341–342
  bridge with breathing 214
  bupropion 83–84, 85, 233, 342–343
  buspirone 342

c
  cabergoline 83, 231–232, 233
  calcitonin 111
  cancer
    arousal disorders 134
    female orgasm disorder 228–229
    orgasm disorders 208
    pelvic and sexual pain disorders 307
  candidiasis 324
  capsaicin 328, 331
  capsacin receptors 260
  cardiovascular disease (CVD) 230
  Case of the Female Orgasm, The (Lloyd) 198
  cataplexy 241
  cauda equina syndrome 164, 168
  cavernous tissue 180
  cell cultures 327
  central nervous system (CNS)
    activation of excitatory systems 44
    anatomy and neurochemistry of sexual desire 25–51
    appetitive and consummatory phases 28–29
    attractivity, proceptivity, and receptivity 30
    Basson’s circular feedback model 30, 31
    CNS agents 85
    excitation, inhibition, and disinhibition of sexual responses 35–40, 37, 38
    disinhibition 39–40
    excitation 36–38
    inhibition 38–39
    female genital arousal disorder 155–156
    female orgasm disorder 224, 232–233
    glutamate in ventrolateral portion of ventromedial hypothalamus 41–42
    incertohypothalamic dopamine 41
    inhibition of inhibitory systems 44
    introduction to sexual desire 25–26
    lordosis 30–31, 33–34, 38–44
    Masters and Johnson's EPOR model 29–30, 29, 35
    melanocortins 41
    menopause 32–33, 45–46
    opioid receptors 39, 42
    orgasm disorders 184–189
ovarian steroid hormones 31–34, 36–44
ovulatory cycles 31–32, 32
pacing behavior 42–43
patterns of brain activation 34–35, 35
relevance of animals to humans 45–46
sexual approach behaviors 40
sexual behavior of human females 31–33
sexual behaviors in animals and humans 26–31
sexual brain stimuli 26–28
sexual positions 33
sexual tipping point model 27, 36, 37, 38
solicitations 40–42
structure of female sexual behavior 28–31
studying CNS regulation of female sexual desire 34–35
treatments for HSDD 45–46, 45
wiring diagram of neurochemical pathways 27, 28
central sensitization 268–271, 268, 301, 306
cerebellum 188
cervix
- anatomy and physiology of arousal 111
- CNS anatomy and neurochemistry of sexual desire 33, 42
- female genital arousal disorder 148
- peripheral and central neural bases of orgasm 183, 185
Changes in Sexual Functioning Questionnaire (CSFQ‐FC) 213
childhood sexual abuse 130–131, 286–288
cholesterol 60–61, 147
cingulate cortex 188–189
circular feedback model (Basson) 30, 31
circular model of sexual response (Whipple and Brash‐McGreer) 199–200, 199
Clinical History of the Medical and Surgical Disease of Women, A (Barnes) 248
clitoral hood 212, 214–216
clitoris
- female genital arousal disorder 152
- gross anatomy 180, 182–183
- histology 179–180, 181
- musculoskeletal management 215
- orgasm disorders 179–180, 182–185
- clitorodynia 167
- clito-urethro-vaginal (CUV) complex 184, 184
CNS see central nervous system
cognition 286
cognitive behavioral therapy (CBT)
- arousal disorders 136–137
- hypoactive sexual desire disorder 55–56
- orgasm disorders 207
- pelvic and sexual pain disorders 306
colposcopy 215, 324–325, 325
complementary and alternative therapies 290
conditioned pain modulation 270
congenital factors 252
consent 303–304
corticosteroids 332
couples/marital therapy
- arousal disorders 137–138
- hypoactive sexual desire disorder 56
- orgasm disorders 206–207
- provoked vestibulodynia 289–290
crying 241
CSFQ-FC see Changes in Sexual Functioning Questionnaire
culture and religion
- arousal disorders 129–130
- orgasm disorders 200–202
- psychological management 54
CUV see clito-urethro-vaginal
CVD see cardiovascular disease
d
Decreased Sexual Desire Screener 80
depth muscle hyperalgesia 264–265, 269
dehydroepiandrosterone (sulfate)
- female genital arousal disorder 148, 150
- hypoactive sexual desire disorder 83, 86
- neurobiological endocrinology 61–63, 71
delayed ejaculation (male) 131–132
delayed orgasm 224
Dennerstein, Lorraine 3
depression
- arousal disorders 129
dyspareunia and vulvovaginal pain 324
- female orgasmic illness syndrome 241
- future developments and research 342–343
- hypoactive sexual desire disorder 22, 78, 79, 83–84
- neurobiological endocrinology 70–71
- provoked vestibulodynia 283, 286
- psychological management 53–54
Index

desire disorder 13

desquamative inflammatory vaginitis 232
desvenlafaxine 84
device strategies 151–152
diabetes mellitus
  arousal disorders 133
  female orgasm disorder 228
  hypoactive sexual desire disorder 77
  neurobiological endocrinology 75
Diagnostic and Statistical Manual of Mental Disorders (DSM)
  arousal disorders 103–104
  female genital arousal disorder 147
  female orgasm disorder 222–223
  female orgasmic illness syndrome 239–240
  hypoactive sexual desire disorder 19–20, 25–26
  International Society for the Study of Women's Sexual Health 2
  orgasm disorders 175–176
  sexual pain disorders 252–253
diazepam 308
dilators 307
dildos, female genital arousal disorder 151–152
direct masturbation training 207
dopamine
  CNS anatomy and neurochemistry of sexual desire 36–38, 40–41, 45
  hypoactive sexual desire disorder 84–85
  neurobiological endocrinology 70
  orgasm disorders 187–188
dry needling 308
DSM see Diagnostic and Statistical Manual of Mental Disorders
dysorgasmia 241
dyspareunia and vulvovaginal pain 319–336
  additional testing 328
  anatomy and physiology 266
  diagnostic and treatment algorithm 329–330
  emerging therapies 334
  epidemiology 250–253
  evaluation 320–328
  histology 327
  hormonally-induced dyspareunia 312
  interdisciplinary treatments 331
  medical management 331–333
  medication history 323–324
  musculoskeletal management 312
  nonmedical treatments 329–330
  nosology 247–248, 319–320
  physical examination 324–327, 325, 326
  provoked vestibulodynia 286–287, 290
  psychosocial history 323
  serum testing 328
  sexual history 320–323, 322–323
  surgical management 333–334
  treatment 328–334
  wet mount and cultures 327
dysphoria 241

e
ear pain 241–242
ED see erectile dysfunction
education and training
  algorithm incorporating specific medical condition 11, 12
  basic structured approach to patients 10–11
  competencies for undergraduate, graduate, and postgraduate levels 7–9, 8
  conclusion and recommendations 12
  disease or therapy specific factors 11, 12
  elements of structured approach to patients 10
  ESSM assessment methods 11–12
  arousal disorder 14
  desire disorder 13
  orgasmic disorder 15
  female sexual health care for practicing clinicians 9–11
  female sexual health care for sexual medicine specialists 11–12
  graduate and postgraduate (level 2 and 3) 9
  International Society for the Study of Women's Sexual Health 3–4
  modified nine-field diagram 11
  orgasm disorders 208
  psychological management 55
  sexuality 9
  sexual medicine 7–16
  undergraduate (level 1) 8–9
  electrical stimulation 307–308
  electromyography (EMG) 215, 307, 328
EMA see European Medicines Agency
embryological factors 252
EMG see electromyography
emotion 284–286, 288
Emotional Brain 342
emotional intimacy see intimacy
empathy 284–285, 288
endocrine disorders see neurobiological endocrinology
endometriosis 301, 326–327
environmental stressors 129
epidural nerve block 242
epilepsy 226–227
EPOR see excitation, plateau, orgasm, resolution
erectile dysfunction (ED) 131, 224
Erotic Stimulus Pathway (Reed) 199
erythema of the ostia of the Bartholin gland 325–326, 325, 326
ESSM see European Society for Sexual Medicine
estradiol
arousal disorders 115, 117
CNS anatomy and neurochemistry of sexual desire 33–34, 36–38, 40–44
dyspareunia and vulvovaginal pain 324
female genital arousal disorder 149–150, 154–155
female orgasm disorder 231
neurobiological endocrinology 61–62, 66, 68
sexual pain disorders 251
estrogen
arousal disorders 114–117
female genital arousal disorder 148–149, 154–155
neurobiological endocrinology 61, 63, 66–71
sexual pain disorders 260–261
vaginal lubrication 112–113
see also ovarian steroid hormones
estradiol receptors 260–261, 267
estrone 61, 63
European Medicines Agency (EMA) 339–340
European Society for Sexual Medicine (ESSM) 11–12, 13–15
excitation, plateau, orgasm, resolution (EPOR) model 29–30, 29, 35
excitatory neurochemical agonists 155–156
exercise training 306
facial pain 241–242
faking orgasm 201
fascial restrictions 300–301
FCAD see female cognitive arousal disorder
FDA see Food and Drug Administration
female cognitive arousal disorder (FCAD) 145, 147
female genital arousal disorder (FGAD) 104
diagnosis 149–150
neurobiological endocrinology 148–150, 153–155
neurologic interventions 156
nosology 147
pathophysiology and medical management 145–160
physiology of female genital arousal responses 146
psychological management 150
risk factors for women with FGAD 147–148
subjective arousal 146–147
treatment 150–156
female orgasm disorder (FOD) diagnosis of women with FOD 229–230
DSM classification 222–223
future developments and research 344
genital responses prior to, during and immediately after female orgasm 221–222
ISSWSH classification 222–224, 233
neurologic disorders 225–229
nosology 222–224, 233
nosology and epidemiology 175–177
pathophysiology and medical management 221–237
prevalence 221
psychological management 229
risk factors for women with FOD 224–229
treatment of women with FOD 230–233
female orgasmic illness syndrome (FOIS) central aversive symptoms 240–241
DSM classification 239–240
ISSWSH classification 239–240
nosology 239–240
pathophysiology and medical management 239–243
peripheral aversive symptoms 241–242
presentation 239
female prostate 183
female sexual arousal disorder (FSAD) 103–104, 147, 344
female sexual distress scale (FSDS) 205
Female Sexual Function Forum 2–3
Female Sexual Function Index (FSFI) arousal disorders 128
female genital arousal disorder 149
hypoactive sexual arousal disorder 81
orgasm disorders 205, 213
Female Sexual Function Questionnaire (SFQ-28) 213
female sexual interest/arousal disorder (FSIAD) 20, 25–26, 104, 344
FGAD see female genital arousal disorder
flibanserin 45–46, 85, 156, 233
FOD see female orgasm disorder
FOIS see female orgasmic illness syndrome
Food and Drug Administration (FDA) 339–341
foot pain 241–242
FSAD see female sexual arousal disorder
FSDS see female sexual distress scale
FSFI see Female Sexual Function Index
FSIAD see female sexual interest/arousal disorder
functional magnetic resonance imaging (fMRI) 186–188, 222
future developments and research 339–348
AMAG Pharmaceuticals 341–342
Emotional Brain 342
historical and regulatory perspective 339–341
marketplace 341–345
other companies and products 344–345
S1 Biopharma 342–343
Strategic Science & Technologies, LLC 343–344

Goldstein, Andrew 3
Goldstein, Irwin 1, 3
gonadotropin releasing hormone 63, 65–66
Graziottin, Alessandra 2
GSM see genitourinary syndrome of menopause
GVD see generalized vulvodynia

h
happy baby pose 214
HAT see Holistic Assessment and Therapies
headache 240–241
hemodynamics
arousal disorders 108–110, 109, 115–116
female genital arousal disorder 146
sex steroid hormones 115–116
sexual pain disorders 265–266
hippocampus 187, 189, 227
histidine methionine 111
histology
clitoris 179–180, 181
dyspareunia and vulvovaginal pain 327
vagina 180, 181
Holistic Assessment and Therapies (HAT) model 203–204
home exercise programs 308
hormonally-induced dyspareunia 312
hormonally-mediated vestibulodynia 167
hormonal therapies
arousal disorders 117
CNS anatomy and neurochemistry of sexual desire 32–33
dyspareunia and vulvovaginal pain 332
female genital arousal disorder 153–155
female orgasm disorder 230–232
future developments and research 342
historical and regulatory perspective 340–341
hypoactive sexual desire disorder 86–87
hormones see sex steroid hormones
HSDD see hypoactive sexual desire disorder
hyperprolactinemia
female genital arousal disorder 148
hypoactive sexual desire disorder 76, 82–83, 85
hypertension 147, 228
hyperthyroidism
hypoactive sexual desire disorder 76, 81–82, 83
neurobiological endocrinology 74–75
hypnosis 290
hypoadic sexual desire disorder (HSDD)
- CNS anatomy and neurochemistry of sexual desire 25–51
- comorbidities 22
- depression 22
- diagnosis 80–82
- direct treatment of HSDD 85–87
- DSM classification 19–20, 25–26
- epidemiology 21–22
- future developments and research 342–343
- historical and regulatory perspective 340–341
- ICD classification 20–21, 25
- ISSWSH classification 20–21, 25
- neurobiological endocrinology 59–75, 82
- nosology 19–21
- older women 21–22
- pathological conditions associated with low sexual desire 75–80
- pathophysiology and medical management 59–100
- PRESIDE study 21–22
- process of care 82, 85
- psychological management 53–57
- therapeutic strategies 82–87
- treatments 45–46, 45
- WISHeS study 22
- hypogastric nervous system 148
- hypogonadotropic hypogonadism
- female genital arousal disorder 148
- hypoactive sexual desire disorder 65, 74, 76, 80
- hypopituitarism 76, 83
- hypothalamus 186
- hypothalamus–pituitary–ovary axis 63–65
- hypothyroidism
- hypoactive sexual desire disorder 76, 81–82, 83
- neurobiological endocrinology 74

ICD see International Classification of Disease
- incertohypothalamic dopamine 41
- individual sex therapy 137–138
- infertility 133
- inflammation
  - pelvic and sexual pain disorders 300, 301
  - persistent genital arousal disorder 164–165
  - sexual pain disorders 251, 266–269
- inhibitory neurochemical antagonists 155–156
- insular cortex 189
- interferon 332
- internal assessment 303–304, 309–310, 326–327
- International Classification of Disease (ICD-10) 20–21, 25, 252
- International Consultation in Sexual Medicine 9
- International Pelvic Pain Society (IPPS) 249, 320
- International Society for the Study of Vulvovaginal Disease (ISSVD) 248–249, 319–320
- International Society for the Study of Women's Sexual Health (ISSWSH)
- approval of sildenafil 1
- arousal disorders 104–105
- dates and locations of annual meetings 3, 4
- dyspareunia and vulvovaginal pain 319–320
- education and training 3–4
- female genital arousal disorder 147
- female orgasm disorder 222–224, 233
- female orgasmic illness syndrome 239–240
- Female Sexual Function Forum 2–3
- history 1–5
- hypoactive sexual desire disorder 20–21, 25
- New Perspectives in Female Sexual Dysfunction 1–2
- on-line forum 2
- orgasm disorders 176, 212
- persistent genital arousal disorder 162–163
- presidency 2–3
- recent developments 4
- sexual pain disorders 249
- interstitial cystitis 259, 326–327, 328
- intimacy
  - arousal disorders 128, 130–132, 136
  - hypoactive sexual desire disorder 54–55, 78
  - orgasm disorders 200
  - pelvic and sexual pain disorders 297, 306
  - provoked vestibulodynia 284–285, 288
  - intravaginal dynamometry 215
- invalidation 285–286, 291
- IPPS see International Pelvic Pain Society
Index

ISSVD see International Society for the Study of Vulvovaginal Disease
ISSWSH see International Society for the Study of Women's Sexual Health

j
Johnson, Virginia see Masters, William and Johnson, Virginia
joint mobilization 305

k
Kaplan, Helen Singer 128, 137, 199
Kegel exercises 288
keratin pearls 212
kisspeptin-1 65, 66, 73

l
labia majora 214, 216
labia minora 214, 216
lactation 71
raloxifene 345
Leiblum, Sandra 2
leiomyoma 327
levothyroxin 83
lidocaine 331
local anesthesia 165–166
lordosis 30–31, 33–34, 38–44
lubrication see vaginal lubrication
luteinizing hormone 63, 65, 66

m
macroprolactinemia 81
magnetic resonance imaging (MRI) 166, 186–188, 222, 328
Malpighian epithelium 180
marital therapy see couples/marital therapy
Masters, William and Johnson, Virginia
EPOR model 29–30, 29, 35
model of arousal 127–128
sex therapy 55–56
sexual response cycle 198–199, 199
masturbation see self-stimulation
medical management
dyspareunia and vulvovaginal pain 331–333
female genital arousal disorder 150–156
female orgasm disorder 230–233
female orgasmic illness syndrome 240–242
hypoactive sexual desire disorder 82–87
persistent genital arousal disorder 162, 166–168
sexual pain disorders 271, 272–273
medication-related pathophysiology 229, 230, 323–324
melanocortins 41
menopause
arousal disorders 116, 117, 133
CNS anatomy and neurochemistry of sexual desire 32–33, 45–46
female genital arousal disorder 148, 149–151, 153–154
future developments and research 342–345
historical and regulatory perspective 339–341
neurobiological endocrinology 63, 65, 68–72
persistent genital arousal disorder 162
surgically induced menopause 75–76, 340–341
menstrual cycle see ovulatory cycle
Meston, Cindy 3, 344
metabolic syndrome
arousal disorders 133–134
female genital arousal disorder 147
female orgasm disorder 228, 230
hypoactive sexual desire disorder 77
neurobiological endocrinology 75
microablative fractional CO2 laser 334
mind–body practices 308
mindfulness techniques
arousal disorders 137
hypoactive sexual desire disorder 55–56
orgasm disorders 207
pelvic and sexual pain disorders 306, 308
provoked vestibulodynia 288, 289
modified nine-field diagram 11
mood 286
MRI see magnetic resonance imaging
MS see multiple sclerosis
multiple sclerosis (MS) 79, 227
muscle weakness 241
musculoskeletal management
adjunctive modalities 306–308
case studies 309, 311, 313
categories of myofascial and musculoskeletal dysfunction 216–217
diagnosis 212
evaluation of musculoskeletal function 212–216
evaluation of pelvic and sexual pain disorders 301–304
history taking 212–213
hormonally-induced dyspareunia 312
musculoskeletal interventions 217
myofascial interventions 217
neuromotor interventions 217
orgasm disorders 211–220
outcomes and follow-up 218
overview of treatment options 217
pathophysiology of sexual pain 299–301
pelvic floor anatomy 296–299, 297–299
persistent genital arousal disorder 216
physical examination 213–215, 213–214
physiotherapy 295–313
screening/prevention 218
sexual pain disorders 251, 295–317
sexual response cycle 211–212
techniques of the physical therapist 304–306
treatment for specific sexual pain diagnoses 308–312
treatments with physician collaboration 308
muted orgasm 224
myofascial dysfunction 216–217
myofascial trigger points 300, 304–305, 308

NANC see nonadrenergic noncholinergic
National Vulvodynia Association (NVA) 249
neural mobilization 305
neural tensioning 302–303
neurobiological endocrinology
early development 67
effects of sex hormones variation on brain, sexual function and behavior 67–75
factors modulating secretion of GnRH and gonadotropins 65–66
female genital arousal disorder 148–150, 153–155
female orgasm disorder 224, 229–232
hypoactive sexual desire disorder 59–75
menopause 63, 65, 68–72
origin of sex steroids 62–63
ovulatory cycle 62–63, 64, 68–72
plasma transport of sex steroids 61–62
puberty 63, 65, 67–68
regulation of hypothalamus–pituitary–ovary axis 63–65
role of androgens 71–72
role of estrogens and progesterone 69–71
role of kisspeptin in female sexual desire 73
role of metabolic diseases 75
role of oxytocin in female sexual desire 73
role of prolactin in female sexual desire 74
role of thyroid hormones in female sexual desire 74–75
secretion and production of sex steroids 62, 62
sex hormone levels 63, 64, 65
steroid biosynthesis and metabolism 60–61, 60
therapeutic strategies for hypoactive sexual desire disorder 82
see also sex steroid hormones
neurochemistry see central nervous system
neurologic dysfunction
female genital arousal disorder 156
female orgasm disorder 225–230
hypoactive sexual desire disorder 79
sexual pain disorders 251
neuromotor interventions 217
neuronal cross-talk 264–265
neuropeptide Y 111
neuroproliferative vestibulodynia 167, 311–312, 328
neurotransmitters
adrenergic regulation 110, 116
afferent pathways 111–112
arousal disorders 110–112, 116
female orgasm disorder 224, 232–233
neurobiological endocrinology 66, 70
nitrergic regulation 110–111, 116
nonadrenergic noncholinergic neurotransmitters 111, 116
orgasm disorders 187–188
New Perspectives in Female Sexual Dysfunction 1–2
New Sex Therapy, The (Kaplan) 137
nipple stimulation 185
nitrergic regulation 110–111, 116
nitric oxide synthase (NOS) 110–111, 115, 180
nociception 257, 258–271, 259, 272–273, 301
nonadrenergic noncholinergic (NANC) neurotransmitters 111, 116
noncontractile connective tissue restriction 216–217
Index

NOS see nitric oxide synthase
nucleus accumbens 186–188
NVA see National Vulvodynia Association

O
obesity 77–78
older women 133
  arousal disorders 133
  CNS anatomy and neurochemistry of sexual desire 32–33, 45–46
  hypoactive sexual desire disorder 21–22
  neurobiological endocrinology 72
  see also menopause
oophorectomy 72, 250
opioid receptors 39, 42
opioids 79–80
  hypoactive sexual desire disorder
  neurobiological endocrinology 66
  sexual pain disorders 260
oral contraception 31–32
  CNS anatomy and neurochemistry of sexual desire 31–32
  dyspareunia and vulvovaginal pain 324
  female genital arousal disorder 149
  hypoactive sexual desire disorder 79
  sexual pain disorders 250–251, 261
orgasm disorders 206
  assessment 205–206
  brain activity and correlates of orgasm 184–189
  brain activity related to orgasm 185
  categories of myofascial and musculoskeletal dysfunction 216–217
  central aversive symptoms 240–241
  clinical context and considerations 202–204
  clito-urethro-vaginal complex 184, 184
  common beliefs/myths around orgasm 204
  concepts and definitions of orgasm 197–198
  corollary animal studies 189
  cultural context and considerations 200–202
  diagnosis 206, 212
  diagnosis of women with FOD 229–230
  DSM classification 175–176, 222–223, 239–240
  epidemiology 176–177
  evaluation of musculoskeletal function 212–216
  expectations and fears 205–206
  functional anatomy 179–184
  functional changes during arousal and orgasm 183–184
  genital responses prior to, during and immediately after female orgasm 221–222
  genital sensation and projections to the brain 185
  gross anatomy of the clitoris 180, 182–183
  gross anatomy of the vagina 182, 183
  help-seeking and point of contact 205
  histology of the clitoris 179–180, 181
  histology of the vagina 180, 181
  history taking 212–213
  innervation of female sexual organs 182
  ISSWSH classification 176, 222–224, 233, 239–240
  musculoskeletal management 211–220
  neurologic disorders 225–229
  nosology 175–176, 212, 222–224, 233, 239–240
  orgasms within the cultural framework 200–202
  outcomes and follow-up 218
  pathophysiology and medical management of FOD 221–237
  pathophysiology and medical management of FOIS 239–243
  peripheral aversive symptoms 241–242
  peripheral and central neural bases of orgasm 179–195
  persistent genital arousal disorder 216
  physical examination 213–215, 213–214
  presentation of FOIS 239
  PRESIDE study 176
  prevalence of FOD 221
  psychological management 197–210, 229
  risk factors for women with FOD 224–229
  role of different brain components in orgasm 185–189
  screening/prevention 218
  sexual response cycle 198–200, 199, 200, 211–212
  treatment of women with FOD 230–233
  vascularization of female sexual organs 182
WISHeS study 177
orgasmic disorder 15
orgasmolepsy 240
ospemifene 155
ovarian steroid hormones see sex steroid hormones
ovulatory cycle
  CNS anatomy and neurochemistry of sexual desire 31–32, 32
  neurobiological endocrinology 62–63, 64, 68–72
  sexual pain disorders 266
oxytocin 73, 222, 233

\( p \)
pacing behavior 42–43
pain see sexual pain
palpation 215
paralysis 241
paraventricular nucleus of the hypothalamus (PVN) 186–187
Parish, Sharon 3
Parkinson’s disease 227
paroxetine 83–84
PCOS see polycystic ovarian syndrome
PE see premature ejaculation
pelvic floor
  adjunctive modalities 306–308
  anatomy 296–299, 297–299
  case studies 309, 311, 313
  coccygeus, piriformis, and obturator internus muscles 298
  cutaneous nerves of the vulva, thigh, and groin 299
  evaluation for musculoskeletal management 301–304
  female orgasm disorder 222, 224, 229, 230
  female pelvic floor anatomy 298
  female urogenital system 297
  hormonally-induced dyspareunia 312
  medical management of dyspareunia and vulvovaginal pain 320, 327
  musculoskeletal management 213–217, 295–317
  pathophysiology of sexual pain 299–301
  persistent genital arousal disorder 163, 166–167
  physiotherapy 295–313
  provoked vestibulodynia 288
  techniques of the physical therapist 304–306
  treatment for specific sexual pain diagnoses 308–312
  treatments with physician collaboration 308
pelvic surgery 148
perineal structures 216–217, 297
peripheral nervous system (PNS)
  female orgasm disorder 225
  orgasm disorders 184–189
  sexual pain disorders 251, 257
  peripheral sensitization 268–270, 268
  persistent genital arousal disorder (PGAD)
    diagnosis 165–166
    etiology of sexual arousal 161–162
    musculoskeletal management 216
    nosology 162–163
    pathophysiology and medical management 161–171
    prevalence of PGAD in the United States 161
    psychological management 162, 166
    risk factors for women with PGAD 163–165
    treatment 166–168
  persistent vulvar pain 249–250
Peyronie's disease 132
PGAD see persistent genital arousal disorder
phantom orgasms 226
phosphodiesterase 5 inhibitors 45–46, 153
  see also sildenafil
physical examination
  dyspareunia and vulvovaginal pain 324–327, 325, 326
  internal assessment 303–304, 309–310, 326–327
  musculoskeletal management 213–215, 213–214
physiotherapy
  adjunctive modalities 306–308
  case studies 309, 311, 313
  dyspareunia and vulvovaginal pain 330–331
  evaluation of pelvic and sexual pain disorders 301–304
  hormonally-induced dyspareunia 312
  pathophysiology of sexual pain 299–301
  pelvic floor anatomy 296–299, 297–299
  pelvic and sexual pain disorders 295–313
  techniques 304–306
  treatment of pelvic and sexual pain disorders 304
  treatment for specific sexual pain diagnoses 308–312
  treatments with physician collaboration 308
pleasure dissociative orgasm disorder 224
PLISSIT Model 204
polycystic ovarian syndrome (PCOS) 134
postcoital dysphoria 241
postcoital tristesse 241
posttraumatic stress disorder (PTSD) 286
pregnancy
  arousal disorders 132–133
  female orgasm disorder 225–226
  orgasm disorders 204
pregnenolone 61
premature ejaculation (PE) 131
premature orgasm 224
PRESIDE study 21–22, 105, 176
process of care 82, 85
progestosterone
  arousal disorders 116–117
  CNS anatomy and neurochemistry of sexual desire 33–34, 40–41, 45
  female genital arousal disorder 148
  neurobiological endocrinology 61, 62, 69–71
sexual pain disorders 261, 266
prolactin
  female genital arousal disorder 150
  female orgasm disorder 222, 231–232
  neurobiological endocrinology 66, 74
prostaglandin E1 152–153, 344
provoked vestibulodynia (PVD)
  alternative treatments 290
  anatomy and physiology 259–260
  assessment 282–284, 283
  childhood victimization 286–288
  cognitive and emotional responses to pain 286
  dealing with psychological distress 288–289
  diagnosis 282
  dyspareunia 286–287, 290
  efficacy of psychological interventions 289–290
  epidemiology 250, 251
  interdisciplinary treatments 290–291
  mood 286
  nosology 248
  pain characteristics 281–282
  peers and the healthcare community 285–286
  predictors of treatment outcome 290
  psychological management 281–294
  psychosocial factors 284–287
relationship dynamics 284–285
sexuality and sexual partners 284
targets of psychological interventions 287–288
treatment 287–291
psychiatric disorders 163, 165, 166
psychological management
  arousal disorders 127–144
  assessment for orgasm disorders 205–206
  assessment of sexual response 134–135, 135, 136
  biopsychosocial model 53–55, 54
  clinical considerations 203–204
  clinical context of orgasm dysfunctions 202–203
  common beliefs/myths around orgasm 204
  concepts and definitions of orgasm 197–198
  couple/marital therapy 56
  cultural context of orgasm dysfunctions 202
  diagnosis for orgasm disorders 206
  dyspareunia and vulvovaginal pain 323, 331
  effects of partner dysfunction in women 131–132
  etiology of sexual arousal 128–131
  expectations and fears 205–206
  female genital arousal disorder 150
  female orgasm disorder 229
  follow-up and referral 208
  health and lifespan considerations 132–134
  help-seeking and point of contact 205
  hypoactive sexual desire disorder 53–57
  integrating psychotherapy in multimodal treatments 56
  models of arousal 127–128
  nonpharmacological treatments for arousal disorders 135–136
  orgasms within the cultural framework 200–202
  outcomes 56
pelvic and sexual pain disorders 306
persistent genital arousal disorder 162, 166
predisposing, precipitating, maintaining, and contextual factors 54
provoked vestibulodynia 281–294
psychotherapy/sex therapy approaches 55–56, 136–138
sexual pain disorders 252
sexual response cycle 198–200, 199, 200
treatment of orgasm disorders 206–208
PTSD see posttraumatic stress disorder
puberty 63, 65, 67–68
pudendal neuralgia 296, 297–298, 327
pudendal neuropathy 147–148
purinergic receptors 113
purinoreceptors 259–261
PVD see provoked vestibulodynia
PVN see paraventricular nucleus of the hypothalamus

q
Q tip test 325–326, 325, 326
quadriped with pelvic tilting 213

r
radiation therapy 148
radiculopathy
  female genital arousal disorder 148, 156
  female orgasm disorder 227–229, 232
  persistent genital arousal disorder 163–164, 164, 166–168
recurrent vulvovaginal candidiasis 267
referred pain 262–265
relational factors
  arousal disorders 130–132, 134–135, 137–138
  commitment and duration 130
  female orgasm disorder 224, 229
  partner dysfunction 131–132
  provoked vestibulodynia 284–285, 288–290
  sex therapy 137–138
religion see culture and religion
rhythmic entrainment model 207–208
ropinirole 233

s
S1 Biopharma 342–343
sacral spinal nerve root (SSNR) radiculopathy
  female genital arousal disorder 156
  female orgasm disorder 227–229, 232
  persistent genital arousal disorder 164, 164, 168
Sarhmann progression 214
scar tissue mobilization 305
screening/prevention
  hypoactive sexual desire disorder 80–82
  musculoskeletal management 218
  pelvic and sexual pain disorders 301–302
seizures 226–227, 240
selective estrogen receptor modulator (SERM) 155
selective serotonin reuptake inhibitors (SSRI) 70–71, 79
self-diagnosis 324
self-disclosure 284–285, 288
self-stimulation 185, 207, 287
sensitization 268–271, 268, 301, 306
sensory neuropathy 163, 165, 167
SERM see selective estrogen receptor modulator
serotonin
  CNS anatomy and neurochemistry of sexual desire 44
  female orgasm disorder 232–233
  hypoactive sexual desire disorder 78
  neurobiological endocrinology 70–71
  serum testing 328
  sex hormone binding globulin 149, 150, 155
sex steroid hormones
  arousal disorders 113–117, 114
  CNS anatomy and neurochemistry of sexual desire 31–34, 36–44
  effect on androgen and estrogen receptors 116–117
  effect on genital blood flow and vaginal lubrication 115–116
  effect on genital tissue structure 114–115
  effects on brain, sexual function and behavior 67–75
  effect on vaginal innervation and smooth muscle contractility 116
  factors modulating secretion of GnRH and gonadotropins 65–66
  female genital arousal disorder 148–150, 153–155
  female orgasm disorder 222, 230–232
  hypoactive sexual desire disorder 59–75
  origin of sex steroids 62–63
  pelvic and sexual pain disorders 301
  persistent genital arousal disorder 165–166
  plasma transport of sex steroids 61–62
  regulation of hypothalamus–pituitary–ovary axis 63–65
  secretion and production of sex steroids 62, 62
  sex hormone levels 63, 64, 65
  sexual pain disorders 250–251, 260–261, 266
  steroid biosynthesis and metabolism 60–61, 60
Index

sex therapy
  arousal disorders 137–138
  hypoactive sexual desire disorder 55–56
  orgasm disorders 204, 205–208
  provoked vestibulodynia 287–288
sexual approach behaviors 40
sexual history
  arousal disorders 134–135, 135
  dyspareunia and vulvovaginal pain 320–323, 322–323
  orgasm disorders 212–213
  provoked vestibulodynia 282, 283
sexuality
  education and training 9
  provoked vestibulodynia 284
  WISHeS study 21–22
sexual pain disorders
  acute and chronic pain 257–258, 267–268, 270
  adjunctive modalities 306–308
  anatomy and physiology of sexual pain 257–280
  arousal disorders 132
  associated factors 252
  background 247
  brain function 270–271
  case studies 309, 311, 313
  Consensus terminology (2015) 249
  DSM classification 252–253
  embryological/congenital factors 252
  epidemiology 249–252
  evaluation for musculoskeletal management 301–304
  female orgasmic illness syndrome 241–242
  future developments and research 345
  genetic factors 250
  hormonal factors 250–251
  hormonally-induced dyspareunia 312
  hormonal regulation 260–261, 266
  impacts 253
  inflammation 251, 266–269
  ISSVD classification 248–249
  medical management of dyspareunia and vulvovaginal pain 319–336
  musculoskeletal management 251, 295–317
  neurologic dysfunction 251
  nociception 257, 258–271, 259, 272–273
  nosology 247–249, 252–253
  novel future directions 271
  pathophysiology of sexual pain 299–301
  pelvic floor anatomy 296–299, 297–299
  peripheral and central sensitization 268–271, 268
  peripheral/neuroproliferation 251
  persistent vulvar pain 249–250
  physiotherapy 295–313
  prevalence 253
  psychological management 252
  psychological management of PVD 281–294
  referred pain 262–265
  somatic and visceral pain 261–265, 262, 265, 271
  subjective pain perception 257–258, 262, 271
  symptom patterns and mechanisms by pain type 263
  techniques of the physical therapist 304–306
  therapeutic mechanisms of action 271, 272–273
  treatment for specific sexual pain diagnoses 308–312
  treatments with physician collaboration 308
  vascular pain 265–266
  see also dyspareunia and vulvovaginal pain; vaginismus; vestibulodynia; vulvodynia
  sexual positions 33
  sexual response cycle 198–200, 199, 200, 211–212
  sexual tipping point model (Perelman) 27, 36, 37, 38
  SFQ-28 see Female Sexual Function Questionnaire
  sildenafil 1, 111, 153, 342–344
  smooth muscle
    arousal disorders 116
    female genital arousal disorder 146, 152–153
    orgasm disorders 180
  sneezing 241
  soft tissue 148–149
  solicitations 40–42
  somatic pain 261–265, 262, 265
  somatovisceral reflex 300
speculum examination  326
spinal cord injury  225–226, 232
SSNR see sacral spinal nerve root
SSRI see selective serotonin reuptake inhibitors
steroid hormones see sex steroid hormones
stigma  285–286
Stork test  213
Strategic Science & Technologies, LLC  343–344
subjective arousal  107–108, 146–147
subjective pain perception  257–258, 262, 271
substance P  111
substances of abuse  79–80
surgically induced menopause  75–76, 340–341
surgical management  333–334

t

tadalafil  153
Tarlov cysts
  female genital arousal disorder  148, 156
  female orgasm disorder  232
  persistent genital arousal disorder  162, 163, 167–168
temporal lobe  227
testosterone
  arousal disorders  116–117
  CNS anatomy and neurochemistry of sexual desire  32, 33–34
dyspareunia and vulvovaginal pain  324
female genital arousal disorder  148–150, 153–155
female orgasm disorder  229, 230–231
future developments and research  342
historical and regulatory perspective  340–341
hyposexual sexual desire disorder  76, 82, 83, 86–87
neurobiological endocrinology  61–63, 67–68, 71–72
sexual pain disorders  250–251, 261
thyroid hormone  74–75, 229–231
tibolone  87
topical agents
  arousal disorders  135
  female genital arousal disorder  152–155
  female orgasm disorder  232
  future developments and research  343–344
transgender surgery  117
transperineal ultrasound  215–216
traumatic brain injury  225
trazodone  86, 343
Trendelenberg test  213

u
ultrasound  307, 328
urethral diverticulum  326–327
urethral prolapse  167
urinary tract symptoms  78

v
vagina
  gross anatomy  182, 183
  histology  180, 181
  orgasm disorders  180, 183, 185
vaginal dilation  288, 307
vaginal laxity  345
vaginal lubrication
  arousal disorders  112–113, 115–116, 132, 135
  female genital arousal disorder  146, 148, 150–151, 153–154
  lubricants/moisturizers  132, 135, 150–151, 153–154
  possible mechanisms of vaginal transudation  112–113, 113
  purinergic receptors and vaginal moisture  113
  sex steroid hormones  115–116

vaginismus
  epidemiology  252–253
  medical management  327
  musculoskeletal management  309–310
  nosology  247–248
  validation  285–286, 291

vardenafil  153
vascular pain  265–266
vasodilation agents  152–153
ventral tegmental area  186–188
vestible  214, 216
vestibule desensitization  306
vestibulodynia
  anatomy and physiology  260, 262, 266–267
  caused by overactive muscles  312
  epidemiology  250–252
  hormonally-mediated vestibulodynia  167
vestibulodynia (cont’d)
  medical management 324, 325, 328, 331–334
  musculoskeletal management 310–312
  neuroproliferative vestibulodynia 167, 311–312, 328
  nosology 248–249
  persistent genital arousal disorder 167
  psychological management of PVD 281–294
  vibrators 151–152
  visceral manipulation 305–306
  visceral pain 261–265, 262, 265, 271, 301
  vortioxetine 84
  vulvar granuloma fissuratum 167
  vulvar lichen sclerosus 325
  vulvar vestibulectomy 333–334
  vulvar vestibulitis syndrome (VVS) 248, 345
  vulvodynia
  epidemiology 250–253
  generalized vulvodynia 248
  medical management 328, 331–334
  musculoskeletal management 310
  nosology 247–249, 320
  vulvoscopy 215, 324–325, 325
  vulvovaginal atrophy 342, 345
  vulvovaginal pain see dyspareunia and vulvovaginal pain
  VVS see vulvar vestibulitis syndrome

W
  wands 307
  wet mount 327
  Women’s International Study of Health and Sexuality (WISHeS) 21–22, 177

Z
  zona reticularis 62–63